C94.30
Mast cell leukemia not having achieved remission
Clinical Classification Guidelines
Inclusion Terms
- Mast cell leukemia with failed remission
- Mast cell leukemia NOS
Medical Intelligence & Overview
Mast cell leukemia is a rare and aggressive form of blood cancer characterized by the uncontrolled proliferation of mast cells, which are a type of immune cell. When this condition is classified with the ICD-10 code C94.30, it specifically refers to cases where the disease has not achieved remission, indicating ongoing disease activity and progression. Mast cell leukemia can significantly impact a patient's health, requiring specialized diagnosis and management. Although it is a rare diagnosis, understanding its nature helps in recognizing the seriousness of the disease and the importance of ongoing medical care.
Causes & Symptoms
Clinical Causes: Genetic mutations in mast cell precursors leading to abnormal growth Chromosomal abnormalities affecting cell regulation (e.g., KIT mutations) Possible familial cases suggesting genetic predisposition Environmental factors are not well established but may influence disease development
Key Symptoms: Severe fatigue and weakness Frequent and severe allergic reactions, including hives, swelling, or anaphylaxis Abdominal pain, nausea, or diarrhea due to gastrointestinal involvement Bone pain or tenderness resulting from marrow infiltration Enlargement of liver, spleen, or lymph nodes Unintentional weight loss Skin lesions such as flushing or redness
Diagnostic & Treatment
Diagnosis Path: Diagnosing mast cell leukemia involves a combination of blood tests, bone marrow examination, and molecular studies. Key steps include: - Blood tests revealing high mast cell counts - Bone marrow biopsy showing infiltration of abnormal mast cells - Immunohistochemistry to confirm mast cell markers - Genetic testing for mutations such as KIT D816V - Additional imaging studies to assess organ involvement It is crucial for healthcare providers to differentiate mast cell leukemia from other mast cell disorders and related hematologic malignancies.
Treatment Protocols: Given the aggressive nature of mast cell leukemia, treatment options focus on controlling symptoms and attempting to reduce disease burden. Common approaches include: - Targeted therapies, such as tyrosine kinase inhibitors (e.g., midostaurin) - Chemotherapy regimens tailored to mast cell malignancies - Supportive treatments to manage allergic symptoms and prevent complications - Corticosteroids to reduce inflammation - Hematopoietic stem cell transplantation in selected cases Each treatment plan is individualized based on patient health status and disease progression. Due to the disease's rarity, management often involves multidisciplinary teams of hematologists, oncologists, and specialists in mast cell disorders.
Clinical Advice & FAQs
Billing Guidance
Is C94.30 a billable ICD-10 code?
Yes, C94.30 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C94.30?
Clinical documentation must specify the nature of Mast cell leukemia not having achieved remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference